HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression.

[1]  S. Fuqua,et al.  ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges , 2021, British Journal of Cancer.

[2]  T. Murakami,et al.  Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update , 2021, Liver Cancer.

[3]  Shijun Zhang,et al.  A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Artemisia annua on the Treatment of Hepatocellular Carcinoma , 2021, Evidence-based complementary and alternative medicine : eCAM.

[4]  Jichuang Wang,et al.  Regulatory mechanisms and therapeutic targeting of vasculogenic mimicry in hepatocellular carcinoma. , 2021, Pharmacological research.

[5]  G. Raj,et al.  Overcoming oncogene addiction in breast and prostate cancers: a comparative mechanistic overview. , 2020, Endocrine-related cancer.

[6]  Zhiyun Yang,et al.  Molecular targets of Yangyin Fuzheng Jiedu Prescription in the treatment of hepatocellular carcinoma based on network pharmacology analysis , 2020, Cancer Cell International.

[7]  M. Rosanova,et al.  Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives , 2020, Cancers.

[8]  G. Dittmar,et al.  Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis , 2020, Journal of clinical medicine.

[9]  M. Talkhabi,et al.  Comprehensive transcriptomic analysis identifies novel regulators of lung adenocarcinoma , 2020, Journal of Cell Communication and Signaling.

[10]  C. Heier,et al.  Estrogen Receptor, Inflammatory, and FOXO Transcription Factors Regulate Expression of Myasthenia Gravis-Associated Circulating microRNAs , 2020, Frontiers in Immunology.

[11]  H. Bian,et al.  Identification of crucial genes based on expression profiles of hepatocellular carcinomas by bioinformatics analysis , 2019, PeerJ.

[12]  G. Giamas,et al.  Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy , 2019, Front. Endocrinol..

[13]  A. Villanueva.  Hepatocellular Carcinoma. , 2019, The New England journal of medicine.

[14]  H. El‐Serag,et al.  Epidemiology and Management of Hepatocellular Carcinoma. , 2019, Gastroenterology.

[15]  A. Bardia,et al.  EMERALD: Phase III trial of elacestrant (RAD1901) vs endocrine therapy for previously treated ER+ advanced breast cancer. , 2019, Future oncology.

[16]  M. Vaccaro,et al.  Initial Steps in Mammalian Autophagosome Biogenesis , 2018, Front. Cell Dev. Biol..

[17]  W. Wu,et al.  Autophagy, NAFLD and NAFLD-Related HCC. , 2018, Advances in experimental medicine and biology.

[18]  Qi Zhao,et al.  Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. , 2017, Nature materials.

[19]  Jiang Chang,et al.  Breast cancer risk-associated variants at 6q25.1 influence risk of hepatocellular carcinoma in a Chinese population , 2017, Carcinogenesis.

[20]  Helene Knævelsrud,et al.  HS1BP3 inhibits autophagy by regulation of PLD1 , 2017, Autophagy.

[21]  K. Liestøl,et al.  HS1BP3 negatively regulates autophagy by modulation of phosphatidic acid levels , 2016, Nature Communications.

[22]  Yu-qin Pan,et al.  Association between estrogen receptor 1 (ESR1) genetic variations and cancer risk: a meta-analysis. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[23]  Feng Xie,et al.  Methylation patterns of estrogen receptor α promoter correlate with estrogen receptor α expression and clinicopathological factors in hepatocellular carcinoma , 2014, Experimental biology and medicine.

[24]  Ray-Jade Chen,et al.  Estrogen receptor α (ESR1) over-expression mediated apoptosis in Hep3B cells by binding with SP1 proteins. , 2013, Journal of molecular endocrinology.

[25]  Weiwei Deng,et al.  Human HS1BP3 induces cell apoptosis and activates AP-1. , 2011, BMB reports.

[26]  J. Jankovic,et al.  A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. , 2007, Archives of neurology.

[27]  J. Jankovic,et al.  A variant in the HS1-BP3 gene is associated with familial essential tremor , 2005, Neurology.

[28]  M. Kubo,et al.  Isolation and characterization of a novel HS1 SH3 domain binding protein, HS1BP3. , 1999, International immunology.